FAQs

---

Myoblast Transfer Therapy (MTT) is a regenerative medicine procedure aimed at repairing defective muscle tissue. It is a treatment approach developed by Peter K. Law, Ph.D. MTT involves transfer of myoblasts (muscle progenitor cells) into patients. The objective of MTT is to revive, restore and/or rejuvenate muscle cells with myoblasts, potentially improving muscle function and treating diseases.

Definition: MTT involves the transfer of myoblasts (muscle progenitor cells) into defective muscles.

Source of Myoblasts: Myoblasts can be harvested from the patient’s own muscle tissue (autologous) or from a donor (allogeneic).

Mechanism: Transferred myoblasts fuse with patient muscle cells to form muscle fibers and improve muscle function.

Procedure: MTT typically involves isolating myoblasts, culturing them, and then injecting them into the patient.

MTT repairs defective muscles, and restores muscle functions, offering an alternative to traditional therapies. MTT is a developing area in regenerative medicine. Studies continue to demonstrate safety and efficacy of MTT in treating various conditions.

1. Immuno-suppression : immunosuppression for 3 weeks after surgery

2. Toxicity / Impurities : 90-100% pure viable myoblasts to avoid toxicity

3. Tumorgenicity : irrelevant

4. Troubles with Differentiation : irrelevant

5. Low Persistence of Transplanted Cells : high persistence of transplanted myoblasts after years

Please reach us at edward.tung@myomedbio.com for further technical questions.